ViroPharma, Inc. - Living in the present and moving on
Page 2

Viropharma also has $176 million cash in the bank and zero debt. If you shy away from pharmaceutical stocks because of the risk factor, this type of revenue and cash flow should put you at ease. Keep in mind VPHM already has a successful drug on the market, Vanconin, and the company will only continue growth pending approval of their new drugs. Provided HCV-796 enters the market, they would have the potential to help the 170 million people suffering from Hepatitis C. Do the math, even the Baywatch babe knows that's enough money to launch VPHM to the big time.

Someone say 'Baywatch'?
Easy there cowboy, and go put some pants on.

Viropharma, Inc. took a nosedive back in March of '06 due to a forecast that was within the range that analysts expected, but not exceeding expectations. I believe VPHM share price is currently undervalued where it trades today, around $13.00 per share. The current share price is trading at 12.5 time's forward 2007 earnings, a very respectable number when compared to other pharmaceuticals.

Taking a quote from Pamela Anderson:

I don't really think about anything too much. I live in the present. I move on. I don't think about what happened yesterday. If I think too much, it kind of freaks me out.

Be like Pam - stop freaking out and realize that VPHM is trading on the lower end of its 52 week range of $7.07 to $24.36. They report Q3 earnings on November 2nd, so now could be the right time to live in the present, buy the stock, and move on.

VPHM 1 year chart:

Article written by: Eric Cheshier
Article posted on: October 19th, 2006